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Osteosarcoma (OS) is the most common primary malignant bone tumor, usually arising in the long bones of adolescents and
young adults. While our knowledge of the molecular pathogenesis of OS has increased in recent years, we are still far from a
comprehensive understanding of the molecular mechanisms of the disease, such as its tumorigenesis, specific mediators of disease
progression, occurrence of chemoresistance, and development of metastasis. After the recent discovery of microRNAs (miRNAs),
their critical roles in molecular biological processes have been of great interest in the cancer research field, including research on
sarcomas. MiRNAs are highly conserved noncoding RNAs which play important roles as oncogenic or suppressive genes to simul-
taneously regulate multiple targets. Recent genome-wide screening using miRNA expression profiles has identified specific miRNA
expression patterns that are associated with the biological and clinical properties of cancers. Additionally, miRNAs and their target
genes or proteins can be potential novel biomarkers or therapeutic targets for cancer. However, there are several challenges that
must be addressed in order to translate miRNA-based therapeutics to the clinical setting. In this review, we summarize the current
understanding of the roles that miRNAs play in OS, and highlight their potential as biomarkers or therapeutic targets.
1. Introduction
Osteosarcoma (OS) is the most common primary malignant
bone tumor with an incidence of 4 to 5 cases per million
(approximately 900 newly diagnosed cases per year in the
United States), mainly arising from the metaphysis of the
long bones of adolescents and young adults [1]. The 5-
year survival rate of the patients with OS has significantly
improved over the past decades to approximately 60–70%
since the introduction of combinatorial chemotherapy [2].
However, a significant proportion of OS patients still respond
poorly to chemotherapy, and they have a risk of local
relapse or distant metastasis even after curative resection of
the primary tumor and intensive chemotherapy. Recently,
novel molecular targeted drugs have emerged, but they
have not been well established for the treatment of OS
[1], in addition, the fundamental molecular mechanisms
underlying the histological heterogeneity, drug resistance,
and development of metastasis in OS remain obscure. Hence,
it is essential to develop novel alternative strategies for the
diagnosis, prediction of the prognosis, and treatment of
patients with OS.
MicroRNAs (miRNAs) are noncoding small RNAs, usu-
ally 18–25 nucleotides in length, which repress translation
and cleave mRNA by base-pairing to the 3′ untranslated re-
gion of the target genes (Figure 1). They have the potential
to regulate various critical biological processes, including the
differentiation, progression, apoptosis, and proliferation of
tumor cells [3]. Since the discovery of the first miRNA, lin-
4, in C. elegans in 1993, it has been estimated that as many
as 1000 miRNA exist in the human genome [4, 5]. More
than 30% of the human genome is regulated by miRNAs
simultaneously targeting multiple genes [6]. The recent dif-
ferences in the miRNA expression profiles detected between
cancer cells and their normal counterparts have revealed
that miRNAs are involved in the pathogenesis of cancer
[7]. In addition, miRNAs may play multiple roles as tumor
suppressors, oncogenes, or both in some cases [8]. These
biological properties of miRNAs may make them useful as
diagnostic and prognostic tools in various cancers, including
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Figure 1: The biogenesis of microRNA in a cell. After the transcription of the miRNA gene in the nucleus, the primary transcript (pri-
miRNA) is cleaved into a precursor molecule (pre-miRNA) with an imperfect stem-loop structure by Drosha. The pre-miRNA is exported
from the nucleus into the cytoplasm by exportin-5. In the cytoplasm, the pre-miRNA is cleaved by Dicer into a dsRNA duplex (miRNA:
miRNA∗), which contains both the single-stranded mature miRNA and its complementary strand (miRNA∗). The miRNA strand is then
incorporated into the RNA-induced silencing complex (RISC) and targets the complementary mRNA sequences via translational repression
or mRNA cleavage.
OS. In this review, we summarize the current knowledge
regarding the involvement of miRNAs in OS (Table 1), with
a focus on their potential application as therapeutic targets.
2. MicroRNA Expression Profiles
2.1. The MicroRNA Expression Profile of Sarcomas. miRNAs
are endogenous RNAs that are highly conserved in the
genomes of most species and can influence various biological
processes, including the development and differentiation of
tumors. To determine the expression pattern of miRNAs,
a miRNA microarray approach has been developed. It has
been reported that the miRNA expression profiles are able to
classify human cancers successfully, whereas the messenger
RNA (mRNA) expression profiles are inaccurate when
applied to the same samples [9]. This result indicates that
the miRNA expression profiles may be more closely linked to
the differentiation of the tumors. Several studies have already
demonstrated that there are unique and differential miRNA
expression patterns for several cancers, which are promising
for their diagnoses [7]. To identify novel miRNA-based bio-
markers, the significance of miRNA expression profiles has
been extensively studied in a diverse group of human sarco-
mas. For instance, Taulli et al. reported that miR-1 and miR-
206 promoted myogenic differentiation to regulate skele-
tal muscle development, and blocked rhabdomyosarcoma
tumor growth in mice xenografts [10]. The reexpression of
thesemiRNAs in rhabdomyosarcoma cells inducedmyogenic
differentiation and inhibited tumor growth. Recently, we
also have identified miR-1 and miR-206, which are both
expressed at a significantly lower level or are absent in chor-
doma cells compared to normal cells [11]. Reintroduction
of miR-1 inhibited the growth of chordoma cells, with
suppression of MET expression. MET is part of a receptor
tyrosine kinase family of oncogenes overexpressed in many
human cancers, including sarcomas, particularly in chor-
doma (94.4%), chondrosarcoma (54.2%), and osteosarcoma
(23.3%) [12]. Importantly, a recent study suggested that the
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Table 1: List of microRNAs involved in regulation of OS.
MicroRNAs Functions in OS
Expression level in
OS samples
Analyzed OS samples
MicroRNA targets in
OS
References
miR-34 family
(miR-34a, 34b and 34c)
P53-related G1 arrest and
apoptosis
Decreased
Cell lines and 107 tumor
samples
CDK6, E2F3, Cyclin
E2, BCL2
[30]
miR-31
P53-related cell
proliferation
N/D Cell lines E2F2 [32]
miR-192, miR-215 P53-related cell cycle arrest N/D Cell lines CDKN1A/p21 [31]
miR140
Chemoresistance to MTX
and 5-FU
Increased in OS with
chemoresistance
Mouse xenografts HDAC4 [56]
miR-215 Chemoresistance to MTX N/D Cell line DTL [57]
miR-92a, miR-99b,
miR-193a-5p, miR-422a
Discriminate good
responders from poor ones
Increased
Cell lines and 27
paraffin-embedded
samples
N/D [59]
miR-132 Decreased
miR-21 Cell invasion and migration Increased
Cell lines and 8 tumor
samples
RECK [41]
miR-199a-3p
Cell proliferation and
migration
Decreased
Cell lines and 12 tumor
samples
MET, mTOR,
STAT3, MCL-1,
BCL-X
[43]
miR-143 Pulmonary metastasis
Decreased in OS
with metastasis
Cell lines and 22 tumor
samples
MMP-13 [46]
Abbreviation: N/D, no data; MTX, methotrexate; 5-FU, 5-Fluorouracil.
Met oncoprotein plays a major role in the metastatic process
in chordoma [13]. Subramanian et al. obtained the miRNA
expression profiles of 27 soft tissue sarcoma samples from
5 histological subtypes (synovial sarcoma, rhabdomyosarco-
ma, leiomyosarcoma, gastrointestinal stromal tumor (GIST),
and liposarcoma) and 7 normal tissue samples [14]. In these
expression profiles, different histological subtypes of sarcoma
had distinct miRNA expression signatures, reflecting the
apparent lineage and differentiation status of the tumors.
With regard to OS, Sarver et al. have generated miRNA
expression profiles for over 300 sarcoma tissue samples repre-
senting 22 different sarcoma subtypes (including 15 OS sam-
ples) and developed a sarcoma miRNA expression database
(S-MED) [15]. Interestingly, an unsupervised clustering
analysis of the miRNA expression profiles showed that OS
formed a single cluster that was distinct from other sarcomas,
such as synovial sarcoma, fibrosarcoma, GIST, andmalignant
fibrous histiocytoma (MFH) [15].
2.2. Dysregulation of miRNA in Osteosarcoma. OS has his-
tological heterogeneity and variability, having not only os-
teoblastic regions, but also chondroblastic and fibroblastic
regions. The presence of a small area of tumor osteoid
enables a pathologist tomake the histological diagnosis of OS
even when regions of fibrous tissue or cartilage are present
[16]. Since a broad range of genetic and epigenetic alterations
can be associated with the osteoblast differentiation pathway,
osteoblasts have been considered as the origin of OS [17].
However, it has recently been demonstrated that the cells of
origin of OS may be a multipotent stem cell (mesenchymal
stem cells). OS is considered to be a differentiation disease
caused by genetic changes that interrupt osteoblast differen-
tiation from mesenchymal stem cells [17, 18]. In the miRNA
expression profiles of OS, the formation of the single distinct
cluster for OS indicates that miRNAs can regulate specific
tissue-lineages during the differentiation of OS [14, 15]. In
other cancers, recent studies also suggested that miRNAs
may be involved in the development of tumors by critically
regulating cancer stem cells, but their involvement in OS is
still unclear [19].
Several studies have investigated the role of microRNAs
in OS using miRNA expression profiles. Maire et al. per-
formedmiRNA expression profiling of seven OS samples and
suggested that the miRNAs provide a novel post-transcrip-
tional mechanism for regulating the expression of specific
pathways and genes related to OS [20]. Recently, Lulla et al.
found twenty-two differentially expressed miRNAs in OS,
and miR-135b, miR-150, miR-542-5p, and miR-652 were
all highly expressed in OS tumor samples compared to
normal osteoblasts [21]. Interestingly, miR-135b, which has
already been shown to play a functional role in normal
osteoblastic differentiation, was significantly increased in OS
[22]. Stabley et al. also found several differentially expressed
miRNAs, including miR-654 and miR-370, in OS xenografts.
Interestingly, the IRS1 gene is a predicted target of miR-370,
and the IRS1 protein interacts with IGF1R, which is usually
highly expressed in OS [23].
The differential expression patterns of miRNAs in OS
may be a consequence of the malignant phenotype, and may
not actually be driving the biology of the tumor. How-
ever, these comprehensive analyses using a relatively high-
throughput screening of the miRNAs will provide insight
into the molecular mechanisms of OS.
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3. TP53-Related miRNAs in Osteosarcoma
TP53 is a well-known tumor suppressor gene involved in
OS [24]. DNA damage induces the phosphorylation of p53,
allowing it to dissociate from Mdm2, which leads to p53-
mediated tumor suppression via cell cycle arrest or apoptosis.
The TP53 gene is mutated in more than 20% of OS, and its
mutations have been demonstrated to be involved in the tu-
morigenesis of OS [25]. In addition, Li-Fraumeni syndrome,
which is characterized by an autosomal dominant mutation
of TP53, leads to the development of multiple malignancies,
including OS [26].
Recently, several miRNAs have been identified as direct
targets of p53 [27]. Among them, the highly conserved
miR-34 family (miR-34a, 34b and 34c) has been an impor-
tant component of the p53 tumor suppressor pathway,
and the expression of these miRNAs was induced by p53
in response to DNA damage or oncogenic stress in multiple
cancers [28, 29]. Although the current knowledge about the
involvement of p53-related miRNAs in OS is limited, He
et al. reported that the miR-34 family induced G1 arrest
and apoptosis via their targets, CDK6, E2F3, Cyclin E2,
and BCL2, in a p53-dependent manner in OS cells [30].
According to an examination of the expression of genetic
and epigenetic alterations of miR-34 in 117 primary OS
samples, the expression of miR-34 was decreased in OS,
and miR-34 inhibited the p53-mediated cell cycle arrest
and apoptosis in OS cells [30]. Additionally, p53 also
induced the upregulation of miR-192, miR-194, and miR-
215 in U2OS cells carrying wild-type p53 [31]. MiR-192
and miR-215 induce the expression of p21, and U2OS cells
transfected with an expression vector for miR-192 formed
significantly fewer colonies than those transfected with that
for a control miR or miR-34a [31]. The loss of miR-31 was
associated with defects in the p53 pathway, and overexpres-
sion of miR-31 significantly inhibited the proliferation of OS
cell lines [32].
A recent study focused on the role of miR-31 in regu-
lating the development of metastatic disease. Valastyan et al.
demonstrated that miR-31 was able to inhibit multiple steps
in the metastatic development of breast cancer [33]. The
silencing of the mRNA targets of miR-31, integrin-α5
(ITGA5), radixin (RDX), and RhoA, reduced local invasion
and motility in vitro and decreased the development of
metastases in a xenograft mouse model of breast cancer [33].
These results suggest that in vivo delivery of miR-31 may
have potential for the prevention of disease progression or
the development of pulmonary metastasis in OS patients.
4. MiRNAs as Potential Biomarkers and
Therapeutic Targets in Osteosarcoma
4.1. The Involvement of miRNAs in the Cell Proliferation and
Metastasis of OS. OS is not only locally aggressive but is
also a systemic disease. Patients with OS can have a relapse
of their tumor or develop distant metastases even after sys-
temic chemotherapy and aggressive surgery. Although lung
metastases are the main cause of death in patients with OS,
the mechanisms are still largely unclear [34]. Consequently,
novel therapeutic targets that can hinder the tumor pro-
gression or the development of metastases have been inves-
tigated, as have prognostic biomarkers [35]. Since miRNAs
have been implicated in the regulation of several important
biological processes, some groups have focused on miRNAs
as an innovative form of therapy for treating OS.
It has been reported that miR-21 is aberrantly overex-
pressed in various cancers and is involved in the pathogenesis
of cancers [36]. MiR-21 also induces cell proliferation, mi-
gration, and invasion by inhibiting the expression of tumor
suppressor proteins in several cancers, such as breast, hepa-
tocellular, and colorectal cancer [37–39]. The inhibition of
miR-21 significantly reduced the lung metastasis of breast
cancer cells in vivo [40]. Ziyan et al. demonstrated that miR-
21 was also significantly overexpressed in OS, and the sup-
pression of miR-21 decreased the invasion and migration
in MG-63 OS cell lines [41]. RECK (reversion-inducing
cysteine-rich protein with kazal motifs) was found to be a
direct target that was negatively regulated by miR-21 in an
OS cell line and human OS samples [41], and it suppressed
the invasion of OS cells by decreasing the activity of matrix
metalloproteinases (MMPs) [42].
In our study on miRNAs and OS, we have examined the
miRNA expression profiles between three OS cell lines and
three osteoblast cell lines [43]. We found that miR-199a-3p,
miR-127-3p, and miR-376 were significantly decreased in the
OS cell lines as compared to osteoblasts, while the expression
of miR-151-3p and miR-191 was increased. Among these
miRNAs, overexpression of miR-199a-3p in OS cell lines
was associated with a significant decrease in cell growth
with G1 arrest. Furthermore, miR-199a-3p suppressed the
expression of oncogenic and antiapoptotic proteins, MET,
mTOR, STAT3, MCL-1, and BCL-X. This suggests that miR-
199a-3p plays a significant functional role in regulating
the proliferation of OS cells. In support of our findings,
the expression of miR-199a-3p was significantly reduced
in several cancers, and restoring the level of miR-199a-3p
induced growth suppression via regulation of mTOR and
MET [44, 45]. Taken together, these findings indicate that
miR-199a-3p can prove to be a promising candidate for gene
therapy, and that attenuated expression of this miRNA is not
specific to a single tumor type.
With respect to the development of pulmonary metasta-
sis in OS, Osaki et al. compared the miRNA expression pro-
files between HOS and 143B OS cells (HOS cells transformed
via v-Ki-ras, resulting in a high rate of metastasis) [46]. The
expression of miR-143 was significantly decreased in 143B
cells compared to HOS cells. Transfection of miR-143 by
systemic injection of miR-143/atelocollagen complexes into
143B cells led to decreased invasiveness and suppression of
lung metastases in vivo. These data are consistent with that
from a previous report which demonstrated that the restora-
tion of miR-143 reduced cell viability and induced apoptosis
in OS cell lines via an antiapoptotic molecule, BCL-2 [47].
Reduced expression of miR-143 has also been reported in
several cancers, such as colorectal, prostate, ovarian, gastric,
and cervical cancer [48–52]. Therefore, miR-143 has been
considered to be a tumor-suppressor miRNA. Chen et al.
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demonstrated miR-143 significantly suppressed colorectal
cancer cell growth by inhibiting KRAS transformation [53].
Akao et al. identified that EPK5 mRNA was one of the target
genes of miR-143 in B-cell lymphoma cell line [54]. In addi-
tion, MMP-13 was identified as one of the miR-143 target
proteins in OS by immunoprecipitation [46]. The expression
of MMP-13 in an immunohistochemical examination in
the tissue samples of OS patients with lung metastasis was
relatively low compared to those without metastasis [46].
4.2. MiRNA Expression and Chemotherapeutic Response in
OS. Advances in chemotherapy have resulted in the most
significant improvement in the outcomes for patients with
OS. Without chemotherapy, the survival rate of patients
with localized OS is less than 20% at 5 years, but systemic
combined chemotherapy (doxorubicin (DOX), cisplatin
(CDDP), methotrexate (MTX), or ifosfamide (IFO)) has
enabled the 5-year survival rates to improve to approximately
60–70% [2]. Although the response to chemotherapy is one
of the most important prognostic factors, more than 40%
of all OS patients still respond poorly to chemotherapy [2].
Only a few therapeutic options have been established for
these poor responders [1, 2, 55]. Moreover, no biomarker has
yet been identified that discriminates between good and poor
responders before the introduction of chemotherapy.
MiR-140 is the first reported miRNA candidate associ-
ated with drug sensitivity in OS tumor xenografts treated
with the chemotherapeutic agents DOX, CDDP, and IFO
[56]. Song et al. revealed that miR-140 showed consistently
high expression levels across all three xenograft models
treated with different drugs. The overexpression of miR-140
caused chemoresistance to MTX and 5-Fluorouracil (5-FU)
and suppressed cell proliferation, inducing G1 and G2 arrest
in both U2OS and MG-63 OS cells, thus indicating that
slowly proliferating or quiescent cells were more resistant to
DNA damaging agents. In addition, miR-140 could nega-
tively regulate histone deacetylase 4 (HDAC4) which inter-
acted with p21 expression, resulting in 5-FU resistance.
The same group reported another miRNA candidate that
plays a significant role in the mechanism of chemoresistance.
MiR-215 decreased the cell proliferation and induced G2
arrest and also increased the chemoresistance to MTX in
U2OS cells and HCT116 (wt-p53) colon cancer cells [57].
Denticleless protein homolog (DTL) was identified as one of
the critical targeted proteins of miR-215 using a bioinformat-
ics approach. The reintroduction of miR-215 suppressed the
expression of the DTL protein. The suppression of DTL by
a DTL-specific siRNA reduced cell proliferation by inducing
G2 arrest, causing a poor response to MTX [57]. Boni
et al. reported that miR-192 and miR-215 influenced the
sensitivity of colorectal cancer to 5-FU [58]. These miRNAs
induced cell cycle arrest with the accumulation of p53 and its
target genes p21 and p27 [58].
Recently, Gougelet et al. examined miRNA expression
profiles to determine the relevance of miRNA expression on
the chemoresistance in 27 OS paraffin-embedded samples,
cell lines and samples from a rat OS model [59]. According
to the supervised hierarchical clustering, five candidate
miRNAs (miR-92a, miR-99b, miR-132, miR-193a-5p, and
miR-422a) showed a statistically significant ability to dis-
criminate good responders to IFO from poor responders.
The targets of these miRNAs detected by the in silico ap-
proach are involved in cell cycle regulation, invasion, and
bone resorption through MAP kinase, TGFß and Wnt path-
ways.
Such discoveries of new miRNAs to predict a response
to chemotherapeutic agents in OS can potentially be used
to stratify patients so that they can be treated with different
preoperative chemotherapy regimens in the future.
5. MiRNA Targeting Therapy and Delivery
The miRNA-based therapeutic approaches for OS may in-
volve two main strategies. One is to block the expres-
sion of oncogenic miRNAs using antisense oligonucleotides
(anti-miR). Antisense oligonucleotides are single-stranded
molecules that form direct bonds by complementary pairing
and work as competitive inhibitors of miRNAs. The other
strategy is to restore the expression of tumor suppressor
miRNAs by introducing miRNA mimics. MiRNA mimics are
synthetic oligonucleotides that are identical to the selected
miRNA. Recently, other novel approaches have been devel-
oped to increase the binding affinity and stability of these
oligonucleotides. Locked nucleic acids (LNAs) are a class of
nucleic acid analogues. LNAs have a methylene bridge that
locks the ribosome conformation and displays unprecedent-
ed binding affinity towards complementary single-stranded
RNA [60]. MiRNA sponges contain multiple complementary
3′ UTR mRNA sites to a miRNA of interest and com-
petitively bind to that miRNA [61, 62]. The advantage of
miRNA sponges is that they are capable of targeting and
inhibiting a family of miRNAs, which is in contrast to
single miRNA targeting with antisense oligonucleotides. For
instance, the inhibition of tumor suppressor miR-31 using
miRNA sponges resulted in the induction of lung metastases
by nonaggressive breast cancer cells [33]. In contrast to miR
sponges, miRNA-masking antisense oligonucleotides (miR-
mask) consist of single-stranded 2′-O-methyl-modified anti-
sense oligonucleotides. MiR-masks effectively depress their
target mRNAs as they are fully complementary to the
predicted miRNA binding sites in the 3′ UTR of the target
mRNA [63].
Currently, the main route for delivery of miRNAs in vivo
is systemic delivery via the intravenous or intraperitoneaal
route [8]. However, the development of more efficient
delivery of miRNAs to the target cells is essential for clinical
applications, because such oligonucleotides are extremely
hydrophilic, sensitive to RNAse degradation, and compar-
atively large, decreasing their ability to penetrate the target
cells [64]. Viral and nonviral strategies have been developed
to overcome these difficulties. The viral strategies have
been widely used for efficient delivery of genes. Although
lentiviruses cannot target specific cells, and residual viral
components can be immunogenic or recombinogenic [65],
effective delivery of miRNAs via a lentivirus has also been
observed [66]. Nonviral strategies generally involve the use
of oligonucleotides with chemical modifications, liposomes,
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Figure 2: Potential candidate miRNAs to be used as biomarkers and therapeutic targets for OS.
polymers, and nanoparticles. Takeshita et al. established at-
elocollagen-mediated delivery for the safe and efficient sys-
temic injection of oligonucleotides and demonstrated the
suppression of OS lung metastasis in mice injected by miR-
143 with atelocollagen [46, 67]. Nanoparticles also hold
promise for the delivery of miRNA more efficiently to the
target cells because of their unique properties, which are
characterized by improved stability, size, and biocompati-
bility, as well as their self-assembly [68]. Recently, miR-34a
delivered by the actively targeted nanoparticles significantly
downregulated the survivin expression in a murine model
of metastatic melanoma [69]. Despite these new discoveries,
there are still several obstacles to overcome prior to the
introduction of clinical testing of miRNA-based treatments.
6. Conclusions
To date, several miRNAs involved in OS have been described.
While specific miRNAs have been shown to be overexpressed
in OS, several miRNAs are also downregulated, as described
above. These results suggest that miRNA-based therapeutic
strategies to restore or inhibit the expression of miRNAs can
serve as a novel therapeutic option for OS.
Altogether, the various studies indicate that miRNAs
have the potential to be promising diagnostic biomarkers,
as well as therapeutic targets, in OS due to their tissue
specificities and critical roles in various biological processes
(Figure 2). Moreover, miRNAs are detectable even in the
sera of patients, leading to additional potential clinical
applications. There has already been significant progress
in the basic knowledge of sarcoma, which has unveiled the
basis of many multiple biological processes. However, the
research on the correlations of miRNAs with OS has just
begun. Although miRNAs will undoubtedly contribute to
the advancement of future clinical therapeutic applications
for OS, further investigations and the establishment of ideal
in vivo delivery systems will be essential.
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